Fore Pharmas latest report ‘Global Nosocomial Infection Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global nosocomial infection drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the nosocomial infection drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Nosocomial Infection: Overview
- Nosocomial Infection Drug Pipeline Overview
- Nosocomial Infection Phase 3 Clinical Trial Drug Pipeline Insights
- Nosocomial Infection Phase 2 Clinical Trial Drug Pipeline Insights
- Nosocomial Infection Phase 1 Clinical Trial Drug Pipeline Insights
- Nosocomial Infection Preclinical Research Drug Pipeline Insights
- Nosocomial Infection Drug Discovery Pipeline Insights
- Geographic Landscape of Nosocomial Infection R&D Activities
- Nosocomial Infection R&D Activities in North America
- Nosocomial Infection R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Nosocomial Infection Drug Market

1. Nosocomial Infection: Disease Definition
2. Nosocomial Infection Drug Pipeline Overview
3. Nosocomial Infection Phase 3 Clinical Trial Drug Pipeline Insights
4. Nosocomial Infection Phase 2 Clinical Trial Drug Pipeline Insights
5. Nosocomial Infection Phase 1 Clinical Trial Drug Pipeline Insights
6. Nosocomial Infection Preclinical Research Drug Pipeline Insights
7. Nosocomial Infection Drug Discovery Pipeline Insights
8. Geographic Landscape of Nosocomial Infection R&D Activities
8.1 Nosocomial Infection R&D Activities in North America
8.2 Nosocomial Infection R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Nosocomial Infection Drug Market
10 Research Methodology Table 1: Nosocomial Infection Drug Pipeline: Phase 3 Clinical Trial

Table 2: Nosocomial Infection Drug Pipeline: Phase 2 Clinical Trial
Table 3: Nosocomial Infection Drug Pipeline: Phase 1 Molecules
Table 4: Nosocomial Infection Drug Pipeline: Preclinical Research
Table 5: Nosocomial Infection R&D Activities by Geography
Table 6: Nosocomial Infection Drug Pipeline: North America
Table 7: Nosocomial Infection Drug Pipeline: Europe
Table 8: Nosocomial Infection Drug Pipeline: Licensing Activities

 Figure 1 : Nosocomial Infection Drug Pipeline Molecules by Stages
Figure 2 : Nosocomial Infection R&D Activities by Geography